Sphingosine-1 phosphate receptor-1 agonist - Sanofi
Alternative Names: S1P1 agonist - SanofiLatest Information Update: 28 Sep 2023
At a glance
- Originator Sanofi
- Class Heart failure therapies
- Mechanism of Action Sphingosine 1 phosphate receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Heart-failure in France
- 31 Aug 2019 Preclinical trials in Heart failure in France (Unspecified) before August 2019
- 31 Aug 2019 Pharmacodynamics data from a preclinical trial in Heart faliure presented at the Annual Congress of the European Society of Cardiology (ESC-2019)